Key Points
- Major shareholder William Scully bought 140,000 Prothena shares for about $1.19 million at an average price of $8.53, increasing his stake by 16.73% to 977,000 shares.
- Prothena missed quarterly expectations, reporting a loss of $0.32 per share versus analysts’ expected loss of $0.23, and revenue of $0.62 million versus a $9.58 million consensus estimate.
- Analysts’ average rating is “Moderate Buy,” with a consensus price target of $20; the stock opened at $8.56, within its one-year range of $7.73 to $11.80.
Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) major shareholder William Scully bought 140,000 shares of Prothena stock in a transaction dated Monday, November 9th. The stock was acquired at an average cost of $8.53 per share, for a total transaction of $1,194,200.00. Following the purchase, the insider directly owned 977,000 shares in the company, valued at approximately $8,333,810. The trade was a 16.73% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Prothena Price Performance
Shares of NASDAQ:PRTA opened at $8.56 on Wednesday. Prothena Corporation plc has a one year low of $7.73 and a one year high of $11.80. The company has a 50 day moving average of $8.62 and a 200-day moving average of $9.18. The stock has a market cap of $439.56 million, a price-to-earnings ratio of -17.83, a P/E/G ratio of 1.87 and a beta of -0.20.
Prothena (NASDAQ:PRTA - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.09). Prothena had a negative return on equity of 9.98% and a negative net margin of 45.44%. The business had revenue of $0.62 million for the quarter, compared to the consensus estimate of $9.58 million. Equities research analysts anticipate that Prothena Corporation plc will post 0.13 earnings per share for the current year.
Analyst Upgrades and Downgrades
PRTA has been the subject of several recent research reports. UBS Group reiterated a "buy" rating on shares of Prothena in a research report on Friday, July 24th. Wall Street Zen downgraded Prothena from a "buy" rating to a "hold" rating in a research note on Saturday, July 25th. Weiss Ratings lowered Prothena from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, October 29th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Prothena in a research note on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Prothena has an average rating of "Moderate Buy" and a consensus target price of $20.00.
Read Our Latest Stock Analysis on Prothena
More Prothena News
Here are the key news stories impacting Prothena this week:
- Positive Sentiment: Major shareholder William P. Scully bought 140,000 shares for about $1.19 million, increasing his stake by 16.73% to 977,000 shares. The sizeable purchase may signal confidence in Prothena. SEC filing
- Positive Sentiment: HC Wainwright maintained its Buy rating and $30 price target, and raised its FY2026 EPS estimate to a loss of $0.44 from a loss of $0.47. Analyst estimates
- Neutral Sentiment: A Zacks article cited a consensus price target implying roughly 120% upside, while cautioning that price targets alone may be unreliable; the article pointed to earnings-estimate trends as a more relevant consideration. Zacks article
- Neutral Sentiment: A short-interest report described a large increase but listed short interest at zero shares and a 0.0-day ratio, making the data difficult to interpret. Short-interest report
- Negative Sentiment: HC Wainwright cut its EPS forecasts for FY2027–FY2029 and FY2030, and lowered its Q4 2026 estimate to a loss of $0.44 per share from a loss of $0.38. The revisions point to weaker expected earnings in several periods, despite the firm’s Buy rating. Analyst estimates
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Versant Capital Management Inc lifted its holdings in Prothena by 179.1% during the third quarter. Versant Capital Management Inc now owns 5,704 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 3,660 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Prothena in the second quarter worth about $148,000. Sei Investments Co. bought a new stake in shares of Prothena in the first quarter worth about $168,000. Chicago Partners Investment Group LLC raised its position in shares of Prothena by 59.8% during the third quarter. Chicago Partners Investment Group LLC now owns 25,779 shares of the biotechnology company's stock worth $211,000 after purchasing an additional 9,650 shares during the period. Finally, Allspring Global Investments Holdings LLC acquired a new stake in shares of Prothena during the third quarter worth about $239,000. 97.08% of the stock is currently owned by institutional investors.
About Prothena
(
Get Free Report)
Prothena Corporation plc (NASDAQ: PRTA) is a clinical-stage biotechnology company focused on discovering and developing novel medicines for serious neurodegenerative and rare peripheral diseases. Its research is centered on disease-causing proteins, including amyloid-beta, alpha-synuclein and transthyretin, with the goal of creating antibody-based therapies that address underlying disease mechanisms. The company's product pipeline has included birtamimab, an investigational antibody being developed for the treatment of AL amyloidosis, and prasinezumab, an investigational alpha-synuclein antibody being developed in collaboration with Roche for certain forms of Parkinson's disease.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
